Drug Trial Radar · NCT06384976
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 20, 2024
Primary completion
Apr 2027
Study completion Jan 2029
Sponsor
- Lead sponsor
- Kyverna TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
Conditions
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis
- MS
Interventions
KYV-101Biological
Anti-CD19 CAR-T cell therapy
Standard lymphodepletion regimenDrug
CYC/FLU
Anti-CD20 mABDrug
Anti-CD20 mAB
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate efficacy of KYV-101Time frame: at least 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University Medical Center
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.